|
CO5180550A1
(es)
|
1999-04-19 |
2002-07-30 |
Smithkline Beecham Corp |
Inhibidores de fab i
|
|
CO5370679A1
(es)
|
1999-06-01 |
2004-02-27 |
Smithkline Beecham Corp |
Inhibidores fab 1
|
|
US6762201B1
(en)
|
1999-10-08 |
2004-07-13 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
US6730684B1
(en)
|
1999-10-08 |
2004-05-04 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
ECSP003699A
(es)
|
1999-10-08 |
2002-04-23 |
Smithkline Beecham Corp |
Inhibidores de fab i
|
|
DE60230934D1
(de)
|
2001-04-06 |
2009-03-05 |
Affinium Pharm Inc |
Fab-i-inhibitoren
|
|
EP1575951B1
(en)
*
|
2002-12-06 |
2014-06-25 |
Debiopharm International SA |
Heterocyclic compounds, methods of making them and their use in therapy
|
|
WO2004082586A2
(en)
|
2003-03-17 |
2004-09-30 |
Affinium Pharmaceuticals, Inc. |
Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
|
|
US8450307B2
(en)
*
|
2004-06-04 |
2013-05-28 |
Affinium Pharmaceuticals, Inc. |
Therapeutic agents, and methods of making and using the same
|
|
CA2632476A1
(en)
*
|
2005-12-05 |
2007-06-14 |
Affinium Pharmaceuticals, Inc. |
Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
|
|
CA2644809A1
(en)
|
2006-03-02 |
2007-09-07 |
Astellas Pharma Inc. |
17 .beta. hsd type 5 inhibitor
|
|
EP2687533B1
(en)
|
2006-07-20 |
2017-07-19 |
Debiopharm International SA |
Acrylamide derivatives as FAB I inhibitors
|
|
WO2008098374A1
(en)
|
2007-02-16 |
2008-08-21 |
Affinium Pharmaceuticals, Inc. |
Salts, prodrugs and polymorphs of fab i inhibitors
|
|
US20130237535A1
(en)
*
|
2010-11-08 |
2013-09-12 |
Nicholas D. Adams |
Fatty acid synthase inhibitors
|
|
KR101720885B1
(ko)
|
2012-06-19 |
2017-03-28 |
데비오팜 인터네셔날 에스 에이 |
(e)-n-메틸-n-((3-메틸벤조푸란-2-일)메틸)-3-(7-옥소-5,6,7,8-테트라히드로-1,8-나프티리딘-3-일)아크릴아미드의전구약물 유도체
|
|
EP3587406B1
(en)
|
2013-03-13 |
2021-01-27 |
Forma Therapeutics, Inc. |
2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
|
|
RS61312B1
(sr)
|
2016-02-26 |
2021-02-26 |
Debiopharm Int Sa |
Lek za lečenje infekcija dijabetskog stopala
|
|
US11690824B2
(en)
|
2018-04-10 |
2023-07-04 |
The General Hospital Corporation |
Antibacterial compounds
|
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
|
CN113382633A
(zh)
|
2018-10-29 |
2021-09-10 |
福马治疗股份有限公司 |
(4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
|
|
MY203711A
(en)
|
2019-02-14 |
2024-07-15 |
Debiopharm Int Sa |
Afabicin formulation, method for making the same and uses thereof
|
|
JP7418475B2
(ja)
|
2019-06-14 |
2024-01-19 |
デバイオファーム インターナショナル エス．エー． |
バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用
|